Ascelia Pharma - Podcast with Deputy CEO Julie Waras Brogren and CSO Andreas Norlin

We have sat down with Ascelia Pharma Deputy CEO Julie Waras Brogren and CSO Andreas Norlin. In this podcast, we are covering the following topics:

Warrant TO1 - Exercise period ongoing:  Subscription period, price, and price calculation. What are gross proceeds at 100% participation?

Feedback from presenting Orviglance abstracts at scientific conferences: RSNA, Society of Abdominal Radiology Congress, ESGAR, ISPOR. What kind of feedback do you receive from the scientific community ie. clinicians, physicians, and KOL?  Do payers, policymakers, healthcare providers, patient organizations, and industry players participate?

Discussions with the FDA: Ascelia Pharma received a positive outcome from the FDA and are ready to file their NDA in mid-2025. What is the format when you discuss with the FDA?

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharam for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup, 11.24 AM, 11 April 2025.